Cannara Biotech (TSX:LOVE) Beta: 0.4103 (As of Jun. 27, 2026)


TSX:LOVE Cannara Biotech Inc TSX:LOVE
92 GF Score
Price C$1.68
GF Value C$1.68
Valuation Fairly Valued
! 4 Warning Signs
View Full Analysis

What is Cannara Biotech Beta?

Cannara Biotech TSX:LOVE +5.00% 92 Beta is 0.4103 as of Jun. 27, 2026. GuruFocus rates TSX:LOVE with a GF Score™ of 92/100 and a GF Value™ of C$1.68 (Fairly Valued). The stock has 4 warning signs investors should review.

Beta is the sensitivity of the expected excess asset returns to the expected excess market returns. As of today (2026-06-27), Cannara Biotech's Beta is 0.4103.


Cannara Biotech  (TSX:LOVE) Beta Explanation

Beta is a measure of the volatility, or systematic risk, of a security or a portfolio in comparison to the market as a whole. We usually compare beta to 1. A beta of 1 indicates that the security's price will move with the market. A beta of less than 1 means that the security will be less volatile than the market. A beta of greater than 1 indicates that the security's price will be more volatile than the market.

Beta is primarily used in the Capital Asset Pricing Model (CAPM) to calculate the Cost of Equity, which can be used in the calculation of WACC %. The formula of Cost of Equity is:
Cost of Equity = Risk-Free Rate of Return + Beta of Asset * (Expected Return of the Market - Risk-Free Rate of Return)


Cannara Biotech Beta Related Terms


Cannara Biotech Beta Historical Data

* Premium members only.

The historical data trend for Cannara Biotech's Beta can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Cannara Biotech Beta Chart

Cannara Biotech Annual Data
Trend Aug18 Aug19 Aug20 Aug21 Aug22 Aug23 Aug24 Aug25
Beta
Get a 7-Day Free Trial 0.00 1.57 0.17 0.03 0.32

Cannara Biotech Quarterly Data
May21 Aug21 Nov21 Feb22 May22 Aug22 Nov22 Feb23 May23 Aug23 Nov23 Feb24 May24 Aug24 Nov24 Feb25 May25 Aug25 Nov25 Feb26
Beta Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.26 0.22 0.32 0.07 -0.35

TSX:LOVE vs ZTS: Beta Comparison

For the Drug Manufacturers - Specialty & Generic subindustry, Cannara Biotech's Beta, along with its competitors' market caps and Beta data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Cannara Biotech Beta vs Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Cannara Biotech's Beta distribution charts can be found below:

* The bar in red indicates where Cannara Biotech's Beta falls into.


TSX:LOVE
92GF Score
Cannara Biotech Inc TSX:LOVE
Beta is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Cannara Biotech Beta Calculation

Beta is the sensitivity of the expected excess asset returns to the expected excess market returns. A stock's beta can be calculated by dividing the product of the covariance of the individual stock's returns and the market's returns by the variance of the market's returns over a specified period. Basically, GuruFocus uses the returns calculated over three-year period.

Frequently Asked Questions Learn more about Beta →
What does a Beta of 0.4103 mean?
Cannara Biotech (TSX:LOVE) has a Beta of 0.4103 as of Jun. 27, 2026. Beta is the sensitivity of the expected excess asset returns to the expected excess market returns. View historical data for Cannara Biotech and its competitors.
Is Cannara Biotech's Beta too high?
Cannara Biotech's current Beta is 0.4103. Overall, Cannara Biotech has a GF Score™ of 92/100 and is considered Fairly Valued, reflecting its overall financial health beyond just this single metric.
How does Cannara Biotech's Beta compare to ZTS?
Cannara Biotech's Beta of 0.4103 can be compared against companies in the Drug Manufacturers industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Beta for a Drug Manufacturers company?
A good Beta depends on the Drug Manufacturers industry context. However, Beta should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Beta mean?
A high Beta can signal that a stock is expensive relative to its fundamentals. Beta is the sensitivity of the expected excess asset returns to the expected excess market returns. View historical data for Cannara Biotech and its competitors. Cannara Biotech's current Beta is 0.4103. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Cannara Biotech stock overvalued right now?
Based on GuruFocus' analysis, Cannara Biotech (TSX:LOVE) is currently considered Fairly Valued. The stock's GF Value™ is C$1.68, compared to a current price of C$1.68 — trading right at its estimated fair value. The current Beta is 0.4103. Cannara Biotech's overall GF Score™ is 92/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Beta calculated?
Beta is calculated from a company's financial statements. For Cannara Biotech (TSX:LOVE), the current Beta is 0.4103 as of Jun. 27, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Cannara Biotech (TSX:LOVE) Overvalued in 2026?

Based on GuruFocus' analysis, Cannara Biotech stock appears to be undervalued. The current stock price of C$1.68 is trading 0% below its estimated GF Value™ of C$1.68. GuruFocus considers Cannara Biotech to be Fairly Valued.

Key valuation signals for TSX:LOVE:

  • Beta: 0.4103
  • GF Value™: C$1.68 vs. price of C$1.68 (0% below fair value)
  • GF Score™: 92/100 with 4 warning signs

No single metric tells the full story. See the TSX:LOVE stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.


Cannara Biotech Business Description

Other Exchanges LOVFF:USA8CB0:Germany
Address 1055 West Georgia Street, Suite 2050, Vancouver, BC, CAN, V6E 3P3
Cannara Biotech Inc is a vertically integrated producer of premium-grade cannabis and cannabis-derivative products for Canadian markets. The company owns two mega Quebec-based facilities. The company operates in in two segments; Indoor cannabis operations segment which includes the cultivation, processing and sale of dried cannabis and cannabis derivatives for the Canadian market and the Real estate operations segment related to the Farnham and Valleyfield building. Majority of the revenue for the company is generated from its Cannabis operations segment. .
92GF Score

Get the complete analysis for TSX:LOVE

Beta is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

C$1.68
Price
C$1.68
GF Value